Johns Hop­kins spin­out Wind­MIL grabs $32.5M to fu­el its work on a next-gen ap­proach to cell ther­a­py

New ap­proach­es to per­son­al­ized can­cer cell ther­a­pies are in no short­age these days. But ex­ecs at Wind­MIL Ther­a­peu­tics, which has just closed a $32.5 mil­lion Se­ries B round, be­lieve they have some­thing “tru­ly dif­fer­en­ti­at­ed.”

The Bal­ti­more-based start­up is tap­ping mem­o­ry T cells re­sid­ing in the bone mar­row — and their in­nate abil­i­ty to rec­og­nize tu­mors — to make what they call a nov­el class of can­cer ther­a­py. Found­ed out of the labs of Johns Hop­kins Uni­ver­si­ty pro­fes­sors Ivan Bor­rel­lo and Kim Noo­nan, Wind­MIL got its name, in part, from the re­sult of re­ac­ti­vat­ing and ex­pand­ing these mem­o­ry T cells ex­tract­ed from the pa­tient’s body: mar­row in­fil­trat­ing lym­pho­cytes, or MILs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.